Concepedia

Author

Kei Amioka

Hiroshima UniversityORCID

Also Known As

K Amioka, Kei Amioka, Kei Morio

39

Publications

321

Citations

10

H-Index

13

Concepts

All Affiliations

Hiroshima UniversityHiroshima University HospitalRIKEN Center for Integrative Medical SciencesHiroshima Red Cross Hospital & Atomic-bomb Survivors HospitalNational Hospital Organization
KA

About

Kei Amioka is an author at Hiroshima University specializing in cancer research, hepatology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Health Sciences

1

1

12

2

Medicine

1

1

12

3

Hepatology

1

1

12

4

Pathology

1

1

12

5

Pharmacology

1

1

12

Kei Amioka

×

10

Publications

244

Citations

10

H-Index

YearCitations

Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma

Yuwa Ando, Tomokazu Kawaoka, Kei Amioka,

Oncology

2021

55

Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice

Yuwa Ando, Tomokazu Kawaoka, Masanari Kosaka,

Cancers

2021

41

Hepatic Arterial Infusion Chemotherapy Combined with Radiation Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombosis of the Main Trunk or Bilobar of the Portal Vein

Yumi Kosaka, Tomoki Kimura, Tomokazu Kawaoka,

Liver Cancer

2021

39

Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma

Masami Yamauchi, Atsushi Ono, Kei Amioka,

Communications Medicine

2023

31

Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma

Yuwa Ando, Tomokazu Kawaoka, Masanari Kosaka,

Liver Cancer

2022

17

Real-world efficacy and safety of durvalumab–tremelimumab as second-line systemic therapy after atezolizumab–bevacizumab in unresectable hepatocellular carcinoma

Ryoichi Miura, Atsushi Ono, Shigeki Yano,

Medicine

2024

13

Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab

Shigeki Yano, Tomokazu Kawaoka, Yusuke Johira,

Medicine

2021

12

Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma

Kei Amioka, Tomokazu Kawaoka, Masanari Kosaka,

Cancers

2022

12

Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein

Takahiro Kinami, Kei Amioka, Tomokazu Kawaoka,

Cancers

2023

12

Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma

Shigeki Yano, Tomokazu Kawaoka, Shintaro Yamasaki,

Cancers

2023

12

Page 1